Correlation Between Hookipa Pharma and Vir Biotechnology

Can any of the company-specific risk be diversified away by investing in both Hookipa Pharma and Vir Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hookipa Pharma and Vir Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Hookipa Pharma and Vir Biotechnology, you can compare the effects of market volatilities on Hookipa Pharma and Vir Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hookipa Pharma with a short position of Vir Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hookipa Pharma and Vir Biotechnology.

Diversification Opportunities for Hookipa Pharma and Vir Biotechnology

0.15

Correlation Coefficient

Hookipa Pharma  Vir Biotechnology

Average diversification

The 3 months correlation between Hookipa and Vir is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Hookipa Pharma and Vir Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vir Biotechnology and Hookipa Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hookipa Pharma are associated (or correlated) with Vir Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vir Biotechnology has no effect on the direction of Hookipa Pharma i.e., Hookipa Pharma and Vir Biotechnology go up and down completely randomly.

Pair Corralation between Hookipa Pharma and Vir Biotechnology

Given the investment horizon of 90 days Hookipa Pharma is expected to under-perform the Vir Biotechnology. But the stock apears to be less risky and, when comparing its historical volatility, Hookipa Pharma is 1.17 times less risky than Vir Biotechnology. The stock trades about -0.21 of its potential returns per unit of risk. The Vir Biotechnology is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  762.00  in Vir Biotechnology on September 27, 2024 and sell it today you would lose (27.00) from holding Vir Biotechnology or give up 3.54% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Hookipa Pharma  vs.  Vir Biotechnology

Hookipa Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Hookipa Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Vir Biotechnology

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Vir Biotechnology are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable forward indicators, Vir Biotechnology is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Hookipa Pharma and Vir Biotechnology

The main advantage of trading using opposite Hookipa Pharma and Vir Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hookipa Pharma position performs unexpectedly, Vir Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will offset losses from the drop in Vir Biotechnology's long position.

The idea behind Hookipa Pharma and Vir Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.